A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419

NCT04494815 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Neuropathic Pain

Interventions

DRUG: SR419
DRUG: active control
DRUG: SR419 placebo
DRUG: active control placebo

Sponsor

Shanghai SIMR Biotechnology Co., Ltd.